MedTrace Logo

Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics

NCT01654120 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2021-02-25

No results posted yet for this study

Summary

The purpose of this study is to determine the effect of adding liraglutide to high dose insulin therapy compared to high dose insulin therapy alone in patients with insulin-treated Type 2 diabetes with insulin requirements of \> 100 units of insulin per day.

Conditions

  • Diabetes Mellitus, Type II

Interventions

DRUG

Liraglutide

SC, 1.8mg,QD, six months to one year

DRUG

Insulin

SC, will be titrated during the study, 4 times a day, 1 year

Sponsors & Collaborators

  • Mountain Diabetes and Endocrine Center

    lead OTHER

Principal Investigators

  • Wendy S Lane, MD · Mountain Diabetes and Endocrine Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01654120 on ClinicalTrials.gov